Last updated on August 2019

A Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in NSCLC Patients With EGFR Mutation Who Failed 1L or 2L EGFR TKI Therapy


Brief description of study

The main purpose of this study is to determine whether nivolumab + chemotherapy is effective as compared to chemotherapy in the treatment of patients with EGFR mutation, NSCLC who failed first line (1L) or second-line (2L) EGFR TKI therapy.

Clinical Study Identifier: NCT02864251

Find a site near you

Start Over

Local Institution

Bunkyo-Ku, Japan
3.29miles
  Connect »

Local Institution

Bunkyo-ku, Japan
3.48miles
  Connect »

Local Institution

Tokyo, Japan
4.22miles
  Connect »

Local Institution

Chuo, Japan
6.96miles
  Connect »

Local Institution

Koto, Japan
9.4miles
  Connect »